Financial Data and Key Metrics Changes - In Q1 2021, U.S. revenue reached $43.7 million, reflecting a 50% growth year-over-year, while total revenue was $44.1 million, up 47% compared to the prior year [21][22] - Non-GAAP U.S. gross margin was 77.9%, consistent with the prior year, while operating expenses increased to $42 million, approximately 95% of sales, reflecting investments in growth [22][24] - Cash usage was approximately $34 million in Q1, primarily driven by capital expenditures, which accounted for over 62% of cash burn [25] Business Line Data and Key Metrics Changes - The company reported a 50% year-over-year growth in revenue, with 77% of revenue coming from new product contributions [4][20] - Average revenue per surgeon grew by 17% year-over-year, and average revenue per case increased by 13% [4][14] - The average products sold per surgery slightly increased to above 1.9 categories [13] Market Data and Key Metrics Changes - The company noted a slight dip in surgical volumes early in Q1, but March showed a breakout month, indicating a potential backlog of procedures [32][33] - The company is focused on expanding its geographical presence, with significant opportunities in major metro areas where it currently lacks representation [46][19] Company Strategy and Development Direction - The company aims to revolutionize spine surgery through the launch of new products like PTP and InVictus, emphasizing clinical distinction and surgeon adoption [4][10] - The strategy includes revitalizing the sales force and expanding the distribution network to enhance market coverage [18][19] - The company is committed to organic innovation and developing a comprehensive product portfolio to address various surgical needs [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory, citing a strong start to 2021 and an increase in full-year revenue guidance to approximately $188 million, implying a 33% year-over-year growth [26][27] - The management highlighted the importance of clinical outcomes and predictive analytics in driving future growth and improving surgical procedures [16][60] - The company is focused on integrating EOS technology to enhance preoperative planning and improve surgical outcomes [60][75] Other Important Information - The company secured approximately $132 million through PIPE funding, ending the quarter with over $190 million in cash, with plans to invest in growth initiatives [24] - The EOS transaction is progressing as planned, with expectations to close during the current quarter [25][26] Q&A Session Summary Question: What is the current marketplace activity and backlog of procedures? - Management noted softness in January and February, with March showing improvement and a potential backlog of procedures to capture [32][33] Question: What is the status of PTP and its adoption? - Management indicated that PTP is in the early phases of adoption, with surgeons starting with simpler procedures and gradually moving to more complex surgeries [40][41] Question: Can you elaborate on the distribution channel and exclusivity? - Management emphasized the need for strong clinical acumen in the distribution network and highlighted significant geographical gaps that need to be filled [46][19] Question: What is the value proposition for EOS? - Management stated that EOS offers immediate value with its new imaging technology, which significantly improves surgical decision-making [75][76]

Financial Performance - U.S product revenue increased by 50% year-over-year, reaching $43.7 million in Q1 2021 compared to $29.1 million in Q1 2020[58] - Total revenue grew by 47% year-over-year, amounting to $44.1 million in Q1 2021 versus $30.1 million in Q1 2020[59] - U.S gross profit increased by 50% year-over-year, reaching $34.1 million in Q1 2021 compared to $22.7 million in Q1 2020[62] - The company maintains a positive net cash position, with $191 million in cash and $60 million in debt[63] Growth Drivers - New product revenue contributed 17% in Q1 2021, compared to 56% in Q1 2020 and less than 10% in FY2018[8] - Revenue per surgeon increased by 17% year-over-year[8,39] - Average revenue per case grew by 13% year-over-year[8] - U.S revenue growth from strategic distribution was 60%[53] Future Outlook - The company anticipates U.S revenue of approximately $188 million, representing a 33% year-over-year increase for FY 2021[68] - Total revenue for FY 2021 is projected to be around $190 million, indicating a 31% year-over-year growth[69] - International revenue is expected to be approximately $2 million, a decrease of 47% year-over-year for FY 2021[69]

Alphatec Holdings, Inc. (NASDAQ:ATEC) Q4 2020 Earnings Conference Call March 4, 2021 4:30 PM ET Company Participants Patrick Miles - Executive Chairman, CEO & President Jeffrey Black - EVP & CFO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Joshua Jennings - Cowen and Company Kyle Rose - Canaccord Genuity Matthew O'Brien - Piper Sandler & Co. Mathew Blackman - Stifel, Nicolaus & Company Jason Wittes - Northland Capital Markets Sean Lee - H.C. Wainwright & Co. Operator Good afterno ...

Alphatec Holdings, Inc. (NASDAQ:ATEC) Q3 2020 Results Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Pat Miles - Chairman and CEO Jeff Black - Chief Financial Officer Conference Call Participants Kyle Rose - Canaccord Patrick Bartoski - Piper Sandler Josh Jennings - Cowen Brooks O'Neil - Lake Street Capital Matthew Blackman - Stifel Jason Wittes - Northland Sean Lee - H.C. Wainwright Operator Good afternoon, everyone. And welcome to Alphatec’s Third Quarter 2020 Financial Results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52024 ALPHATEC HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-2463898 (State or other ju ...